Dr. Leonid N. Volodin, MD

Dr. Volodin practices at UVA University Medical Center in Charlottesville, Virginia.

Dr. Volodin's NPI, 1215148754, was assigned on May 25, 2007. Dr. Volodin holds Virginia license 0101254576.

Dr. Volodin's primary practice is UVA University Medical Center, at 1215 Lee St, Charlottesville, VA 22908 in Charlottesville City. The practice phone is (434) 760-3439.

Dr. Volodin's primary practice is UVA University Medical Center in Charlottesville, Virginia. Dr. Volodin is also affiliated with University Medical Center. The medical group on file is UVA Physicians Group. Dmand AI also links Dr. Volodin to 2 more hospitals, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Volodin practices, 5 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Volodin's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Volodin's licenses on file in 2 states: Virginia and Louisiana.

CMS data shows 400 Medicare services from Dr. Volodin across 7 procedure codes in 2024, for 105 Medicare patients. Medicare paid $26,961 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 105 Medicare patients who saw Dr. Volodin in 2024. The largest group is 65 to 74, with 74 patients. 70% of them have high cholesterol, and 68% have high blood pressure. Their average risk score is 2.78, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Volodin's median patient age at 62, with 45% women.

In 2024, Dr. Volodin wrote 430 Medicare Part D claims for 60 patients. 89% of them were for generic drugs. CMS names the drug for 209 of them, across 6 drugs with 11 or more claims each, at $180,567 in total drug cost. In 2023, CMS named 265 claims across 10 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Volodin for performance year 2024, reported through an alternative payment model (APM). Dr. Volodin accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 6 papers to Dr. Volodin, published from 2012 to 2024. The most frequent topics are Graft vs Host Disease, Pyrazoles and Pyrimidines. Dr. Volodin's most frequent co-authors are Karen K. Ballen, MD, Sunil H. Abhyankar, MD and Michael G. Douvas.

Dmand AI links Dr. Volodin to 1 clinical trial. Conditions studied include Leukemia, Myelogenous, Chronic, BCR-ABL Positive and Hematologic Neoplasms.

CMS Open Payments shows 2 general payments to Dr. Volodin from 2 drug and device companies from 2017 to 2019. Food and beverage make up the largest share, 100% of the total. Jazz Pharmaceuticals Inc. paid the most, $85.